GENFIT S.A Total Assets 2019-2021 | GNFT

GENFIT S.A total assets from 2019 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
GENFIT S.A Annual Total Assets
(Millions of US $)
2021 $333
2020 $227
2019 $347
2018 $271
GENFIT S.A Quarterly Total Assets
(Millions of US $)
2021-12-31 $333
2020-12-31 $227
2020-06-30 $282
2019-12-31 $347
2019-06-30 $364
2018-12-31 $271
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.160B $0.101B
Genfit SA is a biopharmaceutical company. It focuses on the discovery and development of therapeutic and diagnostic solutions in metabolic and liver related diseases. The company's lead products include Elafibranor, Nitazoxanide and TGFTX1 which are in clinical stage. Genfit SA is based in Loos, France.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.383B 9.82
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.475B 16.53
Biohaven Pharmaceutical Holding (BHVN) United States $9.944B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.681B 0.00
Emergent Biosolutions (EBS) United States $1.444B 6.18
Arcus Biosciences (RCUS) United States $1.389B 35.22
Myovant Sciences (MYOV) United Kingdom $0.879B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.509B 0.00
Gelesis Holdings (GLS) United States $0.362B 0.00
Zymeworks (ZYME) Canada $0.321B 0.00
Ambrx Biopharma (AMAM) United States $0.159B 0.00
Enzo Biochem (ENZ) United States $0.114B 23.50
SQZ Biotechnologies (SQZ) United States $0.093B 0.00